For the first time, researchers have documented a significant narrowing of the cardiovascular health gap between older adults with obesity and those with normal weight in high-income countries over the past three decades. A comprehensive analysis published in The Lancet examined nearly one million participants across seven wealthy nations and found that blood pressure and unhealthy cholesterol levels in people over 40 with obesity have converged with those of normal-weight individuals, largely due to increased use of cholesterol-lowering and blood pressure medications.

What Changed Over 30 Years for Older Adults?

The study analyzed health data from 1990 to 2024 across England, the USA, Japan, South Korea, Taiwan, Thailand, and Finland. In the 1990s, adults with obesity typically had higher blood pressure and non-HDL cholesterol (the "bad" cholesterol that increases heart disease risk) compared to people with normal body mass index (BMI). However, the trend reversed dramatically over three decades.

The findings were most striking in older adults aged 60 to 79 years. In England and the USA, older adults with obesity, and especially those with severe obesity (BMI of 35 or higher, roughly 245 pounds for someone 5'10"), now have similar or even lower blood pressure and unhealthy cholesterol levels than older adults with normal BMI by the early 2020s.

"Our study suggests that, in high-income countries, taking medication to lower blood pressure and cholesterol has helped middle-age and older adults lower their cardiovascular risk to levels that are similar to people with normal BMI," stated Prof Majid Ezzati, from the School of Public Health at Imperial College London.

Prof Majid Ezzati, School of Public Health, Imperial College London

Why Did This Convergence Happen?

The primary driver behind this improvement is medication access and use. Over the past three decades, people with obesity were significantly more likely to be prescribed cholesterol-lowering medications like statins and blood pressure medications than those with normal BMI. The gap was especially pronounced in older adults. For example, in England and the USA, approximately 70 to 72 percent of older men with severe obesity were taking cholesterol-lowering medication by the early 2020s, compared with 40 to 48 percent of older men with normal BMI.

This represents a major public health success story. Obesity increases the risk of heart attack, heart failure, and stroke by raising blood pressure and unhealthy cholesterol levels. By aggressively treating these risk factors with medications, healthcare systems have effectively neutralized one of the cardiovascular disadvantages that obesity creates.

How Medications Reduced Cardiovascular Risk

• Statins and Cholesterol Control: These medications lower non-HDL cholesterol, the type most strongly linked to plaque buildup in arteries and heart disease risk.
• Blood Pressure Medications: By keeping blood pressure in a healthy range, these drugs reduce strain on the heart and blood vessels, lowering the risk of heart attack and stroke.
• Intensive Treatment Strategies: Doctors prescribed these medications more aggressively to people with obesity, recognizing their higher baseline cardiovascular risk.

The Concerning Gap: What About Younger Adults?

While the news is encouraging for older adults, the study reveals a troubling blind spot. In younger adults under 40 years old, the cardiovascular health gap between those with obesity and those with normal BMI has not narrowed. The data also shows that cholesterol-lowering and blood pressure medication use is very low in this younger age group, suggesting that medication is indeed the key driver of improvement in older populations.

"While good news for older adults with obesity, our results suggest that cardiovascular health risks remain higher for adults under 40 than for their counterparts with a normal BMI. Early lifestyle interventions, screening and, when appropriate, medication in this younger group should be considered to prevent long-term cardiovascular complications linked to obesity," explained Ysé d'Ailhaud de Brisis, from the School of Public Health at Imperial College London.

Ysé d'Ailhaud de Brisis, School of Public Health, Imperial College London

This finding underscores an important limitation of the medication-focused approach. While treating high blood pressure and cholesterol can mitigate cardiovascular harm associated with obesity, it does not address the broader health consequences of excess weight. Younger adults with obesity may benefit from earlier intervention, including lifestyle changes and preventive screening, before cardiovascular risk factors become entrenched.

What This Means for Weight-Loss Medications

The timing of this research is significant. As weight-loss medications like GLP-1 receptor agonists become more widely available, this study provides important context about the cardiovascular health of people likely to use them. Prof Ezzati noted that the findings "allow the healthcare system to understand how blood pressure and cholesterol treatments benefit the population alongside weight-loss medications".

Prof Ezzati

The convergence in cardiovascular risk factors does not mean that obesity itself is no longer a health concern. Rather, it demonstrates that aggressive medical management can substantially reduce one major pathway through which obesity harms the heart and circulatory system. However, obesity carries multisystem consequences beyond blood pressure and cholesterol, including increased risk of type 2 diabetes, certain cancers, and joint problems.

Important Limitations and Geographic Gaps

The researchers acknowledge that their analysis was limited to seven high-income countries. The findings may not apply to low- and middle-income countries, where access to cholesterol-lowering and blood pressure medications is typically much lower. Additionally, the study could not examine the impact of different medication doses, which would require detailed prescription data.

This research underscores a fundamental truth about modern cardiovascular health: medication access and healthcare engagement matter enormously. For older adults in wealthy nations with obesity, aggressive treatment of blood pressure and cholesterol has successfully reduced their cardiovascular risk to levels comparable to normal-weight peers. However, closing this gap for younger adults and extending these benefits globally remains an important public health challenge.